CRCardiovascular Reviews3083-48802981-8109Bio-Byword Scientific Publishing Pty. Ltd.10.26689/cr.v3i2.10859ArticleKey Points of“Treatment Algorithm for Pulmonary Arterial Hypertension” from the 7th World Symposium on Pulmonary Hypertension and Its Impact on PAH Treatment in Chinahttps://artdesignp.com/journal/CR/3/2/10.26689/cr.v3i2.10859ZhangSonglin,AhmadAshfaq,RenQian,WangHeng,LiLingling,WangXiaoyu,DuYajuan,FanFenling2025322025-07-02Following the 7th World Symposium on Pulmonary Hypertension in 2024, the European Respiratory Journal published an updated treatment algorithm for pulmonary arterial hypertension (PAH), highlighting the emerging role of the activin signal inhibitor (ASI) sotatercept, as a key therapeutic advancement. The updated plan underscores the importance of indicators such as World Health Organization (WHO) functional class and 6-minute walk distance (6MWD) in risk assessment. It advocates for a personalized treatment approach based on risk stratification, encompassing both initial therapy selection and escalation strategies during follow-up. The anticipated introduction of the novel ASI sotatercept in China is expected to expand the therapeutic landscape for PAH management in the country.

Chin K, Gaine S, Gerges C, et al, 2024, Treatment Algorithm for Pulmonary Arterial Hypertension. European Respiratory Journal, 64(4): 2401325.

Sitbon O, Nikkho S, Benza R, et al, 2020, Novel Composite Clinical Endpoints and Risk Scores Used in Clinical Trials in Pulmonary Arterial Hypertension. Pulm Circ, 10: 2045894020962960.

Humbert M, Kovacs G, Hoeper M, et al, 2022, 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. Eur Heart J, 43(38): 3618–3731.

Simonneau G, Montani D, Celermajer D, et al, 2019, Haemodynamic Definitions and Updated Clinical Classification of Pulmonary Hypertension. Eur Respir J, 53: 1801913.

Gaine S, Sitbon O, Channick R, et al, 2021, Relationship Between Time From Diagnosis and Morbidity/Mortality in Pulmonary Arterial Hypertension: Results From the Phase III GRIPHON Study. Chest, 160: 277–286.

Blette B, Moutchia J, Al-Naamani N, et al, 2023, Is Low-Risk Status a Surrogate Outcome in Pulmonary Arterial Hypertension? An Analysis of Three Randomised Trials. Lancet Respir Med, 11: 873–882.

Pan H, McClelland R, Moutchia J, et al, 2023, Heterogeneity of Treatment Effects by Risk in Pulmonary Arterial Hypertension. Eur Respir J, 62: 2300190.

Kim N, Fisher M, Poch D, et al, 2020, Long-Term Outcomes in Pulmonary Arterial Hypertension by Functional Class: A Meta-Analysis of Randomized Controlled Trials and Observational Registries. Pulm Circ, 10: 2045894020935291.

Benza R, Gomberg-Maitland M, Elliott C, et al, 2019, Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. Chest, 156: 232–337.

Weatherald J, Boucly A, Chemla D, et al, 2018, Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Circulation, 137: 693–704.

Badagliacca R, D’Alto M, Ghio S, et al, 2021, Risk Reduction and Hemodynamics With Initial Combination Therapy in Pulmonary Arterial Hypertension. Am J Respir Crit Care Med, 203: 484–492.

D’Alto M, Badagliacca R, Argiento P, et al, 2020, Risk Reduction and Right Heart Reverse Remodeling by Upfront Triple Combination Therapy in Pulmonary Arterial Hypertension. Chest, 157: 376–383.

Boucly A, Beurnier A, Turquier S, et al, 2024, Risk Stratification Refinements With Inclusion of Haemodynamic Variables at Follow-Up in Patients With Pulmonary Arterial Hypertension. Eur Respir J, 63: 2400197.

Veerdonk M, Kind T, Marcus J, et al, 2011, Progressive Right Ventricular Dysfunction in Patients With Pulmonary Arterial Hypertension Responding to Therapy. J Am Coll Cardiol, 58: 2511–2519.

McLaughlin V, Vachiery J, Oudiz R, et al, 2019, Patients With Pulmonary Arterial Hypertension With and Without Cardiovascular Risk Factors: Results From the AMBITION Trial. J Heart Lung Transplant, 38: 1286–1295.

United States Food and Drug Administration, 2024, Sotatercept, visited on July 2, 2024, www.accessdata.fda.gov/drugsatfda_docs/label/2024/761363s000lbl.pdf.

He J, et al, 2022, Characteristics, Goal-Oriented Treatments and Survival of Pulmonary Arterial Hypertension in China: Insights From a National Multicentre Prospective Registry. Respirology, 27(7): 517–528.

Humbert M, McLaughlin V, Gibbs J, et al, 2021, Sotatercept for the Treatment of Pulmonary Arterial Hypertension. N Engl J Med, 384: 1204–1215.

Hoeper M, Badesch D, Ghofrani H, et al, 2023, Phase 3 Trial of Sotatercept for Treatment of Pulmonary Arterial Hypertension. N Engl J Med, 388: 1478–1490.

Humbert M, McLaughlin V, Gibbs JSR, et al, 2025, Sotatercept in Patients With Pulmonary Arterial Hypertension at High Risk for Death. N Engl J Med, 392(20): 1987–2000.